---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121459"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:18:51.096080+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q3 revenue $139M (+42% YoY); Breakthrough Therapy for setrusumab; DTX401 crossover 62% cornstarch reduction

## Summary
- Total revenue $139M, up 42% YoY; Crysvita $98M (+31%), Dojolvi $21M (+29%), Evkeeza $11M.
- Net loss $134M ($1.40/share) vs $160M ($2.23) YoY; operating cash burn $67M in Q3.
- FY2024 guidance reaffirmed: total revenue $530-550M, Crysvita upper end $375-400M, Dojolvi $75-80M.
- Setrusumab (UX143) granted FDA Breakthrough Therapy for osteogenesis imperfecta based on 67% fracture reduction.
- DTX401 Phase 3 crossover patients showed 62% mean cornstarch reduction at week 30; BLA submission planned mid-2025.

## SEC filing metadata
- accession: 0000950170-24-121459
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017024121459/0000950170-24-121459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017024121459/rare-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121459
- JSON: https://secwatch.observer/filing/0000950170-24-121459.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.